These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8438874)

  • 1. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia.
    Raza A; Preisler H; Lampkin B; Lykins J; Kukla C; Gartside P; Sheikh Y; Yousuf N; White M; Barcos M
    Am J Hematol; 1993 Feb; 42(2):147-57. PubMed ID: 8438874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.
    Raza A; Preisler HD; Day R; Yasin Z; White M; Lykins J; Kukla C; Barcos M; Bennett J; Browman G
    Blood; 1990 Dec; 76(11):2191-7. PubMed ID: 2257293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia.
    Raza A; Preisler H; Lampkin B; Yousuf N; Tucker C; Peters N; White M; Kukla C; Gartside P; Siegrist C
    Br J Haematol; 1991 Sep; 79(1):33-9. PubMed ID: 1911386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells.
    Aglietta M; De Felice L; Stacchini A; Petti MC; Bianchi AC; Aloe Spiriti MA; Sanavio F; Apra F; Piacibello W; Stern AC
    Leukemia; 1991 Nov; 5(11):979-84. PubMed ID: 1961040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the in vivo analysis of proliferative characteristics of human leukemia cells in bone marrows.
    Nakamura S; Takeda Y; Kanno M; Yoshida T; Ohtake S; Kobayashi K; Okabe Y; Matsuda T
    Oncology; 1991; 48(4):285-9. PubMed ID: 1716352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies.
    Raza A; Yousuf N; Bohkari SA; Sheikh Y; Akhtar S; Chughtai S; Umerani A; Mehdi SA; Miller MA; Masterson M
    Leuk Res; 1992; 16(3):299-306. PubMed ID: 1560677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
    Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
    Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.
    Poth JL; Johnson PK; George RP; Schrier SL
    Calif Med; 1972 Dec; 117(6):1-11. PubMed ID: 4508367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the rate of DNA synthesis in myeloblasts from peripheral blood and bone marrows of patients with acute nonlymphocytic leukemia.
    Raza A; Yasin Z; Grande C
    Exp Cell Res; 1988 May; 176(1):13-9. PubMed ID: 3371420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Stout ML; Buck SA; Huang X; Vega RA; Becton DL; Ravindranath Y
    Leukemia; 1997 Sep; 11(9):1594-5. PubMed ID: 9305619
    [No Abstract]   [Full Text] [Related]  

  • 15. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
    Martin H; Bruecher J; Claudé R; Hoelzer D
    Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
    Caballero MD; González M; Cañizo MC; Orfao A; Nieto MJ; San Miguel JF
    Leukemia; 1992 Aug; 6(8):856-8. PubMed ID: 1640739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia.
    Raza A; Yousuf N; Abbas A; Umerani A; Mehdi A; Bokhari SA; Sheikh Y; Qadir K; Freeman J; Masterson M
    Blood; 1992 Feb; 79(4):1037-48. PubMed ID: 1737088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
    Lemez P; Gáliková J; Haas T
    Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose cytosine arabinoside in acute myeloid leukemia: remission is not due to differentiation induction.
    Pinkerton PH; London B; Cowan DH
    Am J Hematol; 1985 Aug; 19(4):415-7. PubMed ID: 3861090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.